This segment focuses on the research, development, and clinical trials of immunotherapy treatments for various cancers, with a primary focus on head and neck cancer. The lead product, Multikine, is a key focus, undergoing Phase III clinical trials to evaluate its efficacy and safety. Research and development activities include refining the Multikine formulation, optimizing treatment protocols, and exploring its potential in combination with other therapies. The company utilizes advanced immunological techniques to stimulate the patient's immune system to recognize and eliminate cancer cells. Patient impact is addressed by aiming to improve survival rates and quality of life for cancer patients. Market positioning involves targeting oncology research institutions and establishing partnerships for distribution and commercialization. Future opportunities include expanding the application of Multikine to other cancer types and developing next-generation immunotherapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to stringent clinical trial protocols. Partnerships with pharmaceutical companies are crucial for commercialization and market access.

This segment centers on the Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process. LEAPS is designed to stimulate the human immune system to combat a wide range of diseases, including bacterial, viral, and parasitic infections, autoimmune diseases, allergies, transplantation rejections, and cancer. Research and development activities involve designing and testing LEAPS-based vaccines and therapies for various indications, including rheumatoid arthritis (CEL-2000 and CEL-4000) and COVID-19 (LEAPS COV-19). The technology utilizes advanced immunological and molecular biology techniques to create targeted immune responses. The therapeutic areas covered include infectious diseases, autoimmune disorders, and cancer. Patient impact is addressed by aiming to provide effective treatments for diseases with high unmet medical needs. Market positioning involves establishing strategic partnerships and collaborations to advance the development and commercialization of LEAPS-based products. Future opportunities include expanding the LEAPS platform to address additional diseases and exploring novel applications of the technology. Regulatory and clinical aspects involve conducting preclinical studies and clinical trials to demonstrate safety and efficacy. Partnerships with research institutions and pharmaceutical companies are essential for advancing the LEAPS platform.